about
Crk-associated substrate lymphocyte type is required for lymphocyte trafficking and marginal zone B cell maintenanceExpression profiling of immature thymocytes revealed a novel homeobox gene that regulates double-negative thymocyte developmentNonredundant roles of the elongation factor MEN in postimplantation developmentAML1/Runx1 negatively regulates quiescent hematopoietic stem cells in adult hematopoiesis.T cell acute lymphoblastic leukemia arising from familial platelet disorder.Comparison between pulsed high-dose dexamethasone and daily corticosteroid therapy for adult primary immune thrombocytopenia: a retrospective study.Development of hairy cell leukemia in familial platelet disorder with predisposition to acute myeloid leukemia.Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development.AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis.Runx1/AML-1 ranks as a master regulator of adult hematopoiesis.Acute myeloid leukemia with cryptic CBFB-MYH11 type D.Structure and function of cas-L and integrin-mediated signaling.Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.A role for RUNX1 in hematopoiesis and myeloid leukemia.Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma.An indeterminate result of QuantiFERON-TB Gold In-Tube for miliary tuberculosis due to a high level of IFN-γ production.Intracellular reactive oxygen species mark and influence the megakaryocyte-erythrocyte progenitor fate of common myeloid progenitors.AML1 enhances the expression of leukotriene B4 type-1 receptor in leukocytes.Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells.Acute eosinophilic pneumonia is a non-infectious lung complication after allogeneic hematopoietic stem cell transplantation.AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues.The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP.HIV-negative, HHV-8-unrelated primary effusion lymphoma-like lymphoma: report of two cases.The first case of blastic plasmacytoid dendritic cell neoplasm with MLL-ENL rearrangement.Unique association of Waldenström macroglobulinemia with optic neuritis and monoclonal T cell expansion.Prediction model for CD34 positive cell yield in peripheral blood stem cell collection on the fourth day after G-CSF administration in healthy donors.A case of Schizophyllum commune sinusitis following unrelated cord blood transplantation for acute lymphoblastic leukemia.Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia.A new three-way variant t(15;22;17)(q22;q11.2;q21) in acute promyelocytic leukemia.Pulmonary lymphocyte-rich classical Hodgkin lymphoma with early response to ABVD therapy.Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan.Impaired spermatogenesis and male fertility defects in CIZ/Nmp4-disrupted mice.Serial profile of vitamins and trace elements during the acute phase of allogeneic stem cell transplantation.Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy.FDG-PET is effective in the detection of granulocytic sarcoma in patients with myeloid malignancy.[Molecular mechanisms in the development of acute myeloid leukemia].Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation.Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl.Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF.A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period.
P50
Q28271116-07D5E413-7A38-413C-BA60-5601E65F379EQ28588794-8E519151-E35D-4EC9-93A3-7C4085DB3E1DQ28594021-B16A98E1-F7D8-42BD-B75A-B99DB2412DFEQ33324585-AD12E7DC-ACE5-4D16-8AD8-7F4972F874CAQ33390143-D3C4994E-2518-48A6-A6BD-E1254DDDFDC2Q33400741-D84738BE-4516-456F-8B60-7A50D38364DCQ33409963-CEF53459-58E0-4C42-9DEB-9A80102735FFQ34197865-F8875297-09EE-4FA1-9EF1-0931DBF39FDBQ34299077-C017B351-D814-4082-8258-98A9F9056AA6Q35814888-45298659-2121-43A3-BBC7-004F2062B93DQ36449815-9E565E32-733D-448C-B675-CD4C10802F5AQ36752938-75D0E00C-D5FC-42B7-A05D-2DB0E8BDDCD9Q37949668-7D6643D4-A5E6-444B-9C72-FA83D1C381E5Q38101285-55112AA8-6F81-481C-ADEE-DB666795B1ADQ38112911-EFF1EF8A-C9B1-4294-AB7D-4F68606D342BQ38183752-3D01FCC8-37C4-4CAF-8510-97438C25912CQ39069253-258A4EE8-88E8-4E1B-ACC7-229B7CEEFB9EQ39714289-4C2D1376-337F-4614-9F0A-5CBA14B33C4BQ39953712-9D7C1171-83E8-466A-8A1A-5B09B8CBB6F2Q40400005-F1B98ECA-21BA-4A03-AA69-3C6C1C8D7318Q40594028-8B4B5DE5-4798-4896-B17B-11E4622B71CBQ40736865-652A9665-8DA8-4112-B180-B17E376AAFDFQ43210928-20A25730-E58C-46D7-ADAB-847B5E8808A2Q43552310-A3E9F6A5-2003-4571-BE9D-370DCEDDCD95Q43902500-F2A62E91-8771-46AA-9803-B46588B2AE83Q43911928-D1333530-0CBF-44BB-A5F2-CCE48E542E4EQ44735067-5AEEFDE1-7E8A-49A7-87DC-9249ED596404Q45782361-54CF8275-05B4-444F-B861-0545574B2D23Q46134790-BBB6D752-4EDD-4DD5-859E-ABDA1BE0A0D2Q46254080-A5AC225E-72FC-4727-ABE3-796146736F69Q46534692-DB98F7C3-5B6A-41C8-BE68-71F0B3112BAFQ47365909-A3DD1DC9-B65F-4F3A-B289-C9C9F69FB4B3Q51767027-7C4713D1-3858-427F-B5BE-7B5BFBDF0D3EQ53059192-051D564C-531D-42CD-9DA4-58A30A3CDA17Q53293902-3D1BDB88-C690-4523-B98F-3880F47EECCBQ53305317-EBB69349-69C4-4FB5-B491-221B34E6765CQ54515107-9CD3F157-0DBB-413A-919D-9AACA77E9039Q54567366-2A2897BA-F241-4B94-8BB6-B80BCC9B2966Q54574285-C7959DC3-AE6B-40B5-AC86-137922B71D2FQ54638425-AF34EC94-9546-4B7A-86A6-7C3626439702
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Motoshi Ichikawa
@ast
Motoshi Ichikawa
@en
Motoshi Ichikawa
@es
Motoshi Ichikawa
@nl
Motoshi Ichikawa
@sl
type
label
Motoshi Ichikawa
@ast
Motoshi Ichikawa
@en
Motoshi Ichikawa
@es
Motoshi Ichikawa
@nl
Motoshi Ichikawa
@sl
prefLabel
Motoshi Ichikawa
@ast
Motoshi Ichikawa
@en
Motoshi Ichikawa
@es
Motoshi Ichikawa
@nl
Motoshi Ichikawa
@sl
P106
P21
P31
P496
0000-0001-6497-0848